Originator Organization |
Active Organization- |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC42H51Cl2N11O8 |
InChIKeyPVZCLGQITBYVPH-UHFFFAOYSA-N |
CAS Registry2624181-69-5 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | CN | 01 Mar 2021 | |
Neoplasms | Preclinical | CN | 01 Mar 2021 |